Solid waste program fiscal year 1997 multi-year work plan WBS 1.2.1

This document provides the technical baseline, work breakdown structure, schedule baseline, cost baseline, and execution year for the solid waste program

Cytoplasmic Domain of the 180-kD Bullous Pemphigoid Antigen, a Hemidesmosomal Component: Molecular and Cell Biologic Characterization

Using a serum sample of a bullous pemphigoid (BP) patient we have isolated a cDNA clone encoding a portion of a 180-kD polypeptide component of the hemidesmosome, the “BP180 autoantigen.” The identity of the clone was confirmed by the generation of a fusion protein antibody that recognizes BP180 in both a basal epithelial cell extract of bovine tongue and extract of human epidermal cells. Immunoelectron microscopy indicates that the 588-bp cDNA encodes a cytoplasmic fragment of BP180. Furthermore, the wide species reactivity of the fusion protein suggests that this portion of BP180 is highly conserved. In cultured human epidermal cells processed for confocal immunofluorescence microscopy, the fusion protein antibody generates a punctate cell substrate-associated staining pattern that is similar to that seen using BP230 antibodies. Using the original BP180 cDNA we have now isolated additional cDNA clones encoding approximately 1800bp of BP180 the 3' sequence of which overlaps with the sequence detailed in Giudice et al (J Clin Invest 87:734–738, 1991). Secondary structural analyses have been undertaken on the predicted amino acids encoded by the 1800bp. These suggest that the collagen-like sequences of BP180 described by Giudice et al (ibid.) are separated by a putative transmembrane region from the domain of BP180 recognized by our fusion protein antibody. Indeed, BP180 appears to belong to a relatively rare group of proteins in which the N-terminus is located in the cytoplasm and the C-terminus is extracellular. We detail some preliminary biochemical experiments in support of this hypothesis. We discuss possible functions of BP180 and BP230 in the hemidesmosome

Blood group antigens and integrins as biomarkers in head and neck cancer: Is aberrant tyrosine phosphorylation the cause of altered Α6Β4 integrin expression?

Head and neck cancer is a capricious disease that varies greatly in its clinical behavior. The development of biomarkers that can distinguish between biologically aggressive and indolent tumors has been a long term goal of our laboratories. Predictive markers applicable to biopsy specimens should facilitate clinical management through early identification of patients at greatest risk for early relapse or metastatic spread. Two prominent cell surface markers that we identified by raising monoclonal antibodies to squamous cell carcinomas are blood group antigens and the A9 antigen/Α6Β4 integrin. Both of these markers are abnormally displayed in squamous cancers of the head and neck and serve as indicators of early relapse. Loss of blood group antigen expression is a stronger single indicator than is overexpression of the Α6Β4 integrin. However, use of both markers together is a stronger predictive indicator than is either alone. We know little about the function of the blood group antigens in squamous cells except that the mature antigens are associated with differentiation. Similarly, the function of the Α6Β4 integrin is also not fully understood. Integrin Α6Β4 is thought to serve as an extracellular matrix receptor, but its ligand has not been confirmed. In resting epithelium, the Α6Β4 integrin is polarized to the basal aspect of the basal cell as a component of the hemidesmosome, the anchoring structures of the epithelia. This basal polarization is lost in migrating normal squamous cells and squamous carcinomas. Tyrosine phosphorylation of the Β4 subunit is absent or greatly reduced in malignant cells and this may be a critical signal for subcellular localization of Α6Β4 and cell anchoring. On the basis of our current experimental results, we postulate that tyrosine phosphorylation of the Β4 subunit is a reversible signal that regulates cell migration in normal and malignant cells, and may therefore be an important initial event in the metastatic cascade.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/38454/1/240531033_ftp.pd

Technical basis for exemption from alpha surveys for personnel, material, and equipment in the 324 facility

The purpose of this document is to establish the technical basis for characterizing grouted B-Cell waste for disposal at the Hanford Burial Grounds using the 3-82B shipping cask. The scope of this document includes establishing the technical basis for loading the shipping package, an HN-200 Grout Container, to ensure that: (1) the amount of material in the grout container does not exceed the 100 nCl alpha/g limit that would cause the waste to be designated as ''greater that Category 3'' (GC3) or transuranic (TRU) waste (2) the amount of heat generated by the waste in the grout container does not exceed the 60 Watt heat generation limit established in the 3-82B shipping cask Safety Analysis Report (SAR); and (3) the dose rate on the surface of the shipping cask after loading does not exceed the 200 mrem/h limit established in the cask SAR. This document establishes the technical basis for performing measurements and analyses that will ensure that none of these three limits are exceeded

324 Facility B-cell quality process plan

Quality Process Plan for the Restart of Cell Hot-Work. Addition of Table 6a

B cell remote-handled waste shipment cask alternatives study

The decommissioning of the 324 Facility B Cell includes the onsite transport of grouted remote-handled radioactive waste from the 324 Facility to the 200 Areas for disposal. The grouted waste has been transported in the leased ATG Nuclear Services 3-82B Radioactive Waste Shipping Cask (3-82B cask). Because the 3-82B cask is a U.S. Nuclear Regulatory Commission (NRC)-certified Type B shipping cask, the lease cost is high, and the cask operations in the onsite environment may not be optimal. An alternatives study has been performed to develop cost and schedule information on alternative waste transportation systems to assist in determining which system should be used in the future. Five alternatives were identified for evaluation. These included continued lease of the 3-82B cask, fabrication of a new 3-82B cask, development and fabrication of an onsite cask, modification of the existing U.S. Department of Energy-owned cask (OH-142), and the lease of a different commercially available cask. Each alternative was compared to acceptance criteria for use in the B Cell as an initial screening. Only continued leasing of the 3-82B cask, fabrication of a new 3-82B cask, and the development and fabrication of an onsite cask were found to meet all of the B Cell acceptance criteria

324 Facility B-cell quality process plan

Quality Process Plan for the Restart of Cell Hot-Work. Addition of Table 5B

ADVANCES IN HEXAVALENT CHROMIUM REMOVAL AT HANFORD

At the Hanford Site, chromium was used as a corrosion inhibitor in the reactor cooling water and was introduced into the groundwater as a result of planned and unplanned discharges from reactors during plutonium production since 1944. Beginning in 1995, groundwater treatment methods were evaluated leading to the use of pump and treat facilities with ion exchange using Dowex 21 K, a regenerable strong base anion exchange resin. This required regeneration of the resin, which is currently performed offsite. Resin was installed in a 4 vessel train, with resin removal required from the lead vessel approximately once a month. In 2007, there were 8 trains (32 vessels) in operation. In 2008, DOE recognized that regulatory agreements would require significant expansion in the groundwater chromium treatment capacity. Previous experience from one of the DOE project managers led to identification of a possible alternative resin, and the contractor was requested to evaluate alternative resins for both cost and programmatic risk reductions. Testing was performed onsite in 2009 and 2010, using a variety of potential resins in two separate facilities with groundwater from specific remediation sites to demonstrate resin performance in the specific groundwater chemistry at each site. The testing demonstrated that a weak base anion single-use resin, ResinTech SIR-700, was effective at removing chromium, had a significantly higher capacity, could be disposed of efficiently on site, and would eliminate the complexities and programmatic risks from sampling, packaging, transportation and return of resin for regeneration. This resin was installed in Hanford's newest groundwater treatment facility, called 100-DX, which began operations in November, 2010, and used in a sister facility, 100-HX, which started up in September of 2011. This increased chromium treatment capacity to 25 trains (100 vessels). The resin is also being tested in existing facilities that utilize Dowex 21 K for conversion to the new resin. This paper will describe the results of the testing, performance in the facilities, continued optimization in the pump and treat facilities, and the estimated savings and non-tangible benefits of the conversion